BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34291733)

  • 1. Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.
    Ranjan S; Goihl A; Kohli S; Gadi I; Pierau M; Shahzad K; Gupta D; Bock F; Wang H; Shaikh H; Kähne T; Reinhold D; Bank U; Zenclussen AC; Niemz J; Schnöder TM; Brunner-Weinzierl M; Fischer T; Kalinski T; Schraven B; Luft T; Huehn J; Naumann M; Heidel FH; Isermann B
    Nat Commun; 2017 Aug; 8(1):311. PubMed ID: 28827518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
    Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treg-targeted IL-2/anti-IL-2 complex controls graft-
    Thiolat A; Pilon C; Caudana P; Moatti A; To NH; Sedlik C; Leclerc M; Maury S; Piaggio E; Cohen JL
    Haematologica; 2024 Jan; 109(1):129-142. PubMed ID: 37706355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMPK Drives both Glycolytic and Oxidative Metabolism in Murine and Human T Cells During Graft-versus-host Disease.
    Ramgopal A; Braverman E; Sun LK; Monlish D; Wittmann CJ; Kemp F; Qin M; Ramsey MJ; Cattley RT; Hawse W; Byersdorfer C
    Blood Adv; 2024 May; ():. PubMed ID: 38810258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease.
    Moe A; Rayasam A; Sauber G; Shah RK; Doherty A; Yuan CY; Szabo A; Moore BM; Colonna M; Cui W; Romero J; Zamora AE; Hillard CJ; Drobyski WR
    J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38662453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enforced gut homing of murine regulatory T cells reduces early graft-versus-host disease severity.
    Larson JH; Jin S; Loschi M; Bolivar Wagers S; Thangavelu G; Zaiken MC; McDonald-Hyman C; Saha A; Aguilar EG; Koehn B; Osborn MJ; Panoskaltsis-Mortari A; Macdonald KPA; Hill GR; Murphy WJ; Serody JS; Maillard I; Kean LS; Kim SV; Littman DR; Blazar BR
    Am J Transplant; 2023 Aug; 23(8):1102-1115. PubMed ID: 36878433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1-mediated immune suppression during GVHD.
    Wang Y; He S; Calendo G; Bui T; Tian Y; Lee CY; Zhou Y; Zhao X; Abraham C; Mo W; Chen M; Sanders-Braggs R; Madzo J; Issa JP; Hexner EO; Wiest DL; Reshef R; Xue HH; Zhang Y
    Blood; 2024 Jan; 143(2):166-177. PubMed ID: 37871574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch signaling drives intestinal graft-versus-host disease in mice and nonhuman primates.
    Tkachev V; Vanderbeck A; Perkey E; Furlan SN; McGuckin C; Gómez Atria D; Gerdemann U; Rui X; Lane J; Hunt DJ; Zheng H; Colonna L; Hoffman M; Yu A; Outen R; Kelly S; Allman A; Koch U; Radtke F; Ludewig B; Burbach B; Shimizu Y; Panoskaltsis-Mortari A; Chen G; Carpenter SM; Harari O; Kuhnert F; Thurston G; Blazar BR; Kean LS; Maillard I
    Sci Transl Med; 2023 Jun; 15(702):eadd1175. PubMed ID: 37379368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty Acids Play a Critical Role in Mitochondrial Oxidative Phosphorylation in Effector T Cells in Graft-versus-Host Disease.
    Nakano H; Sato K; Izawa J; Takayama N; Hayakawa H; Ikeda T; Kawaguchi SI; Mashima K; Umino K; Morita K; Ito R; Ohno N; Tominaga K; Endo H; Kanda Y
    Immunohorizons; 2024 Mar; 8(3):228-241. PubMed ID: 38441482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Confounding Role of Graft-Versus-Host Disease in Animal Models of Cancer Immunotherapy: A Systematic Review.
    Ashraf H; Heydarnejad M; Kosari F
    Arch Iran Med; 2024 Mar; 27(3):159-167. PubMed ID: 38685841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New mechanisms of GVHD suppression by Tregs.
    Lederer K; Maillard I
    Blood; 2023 Apr; 141(14):1655-1657. PubMed ID: 37022736
    [No Abstract]   [Full Text] [Related]  

  • 12. AMPK Metabolism in the B Lineage Modulates Humoral Responses.
    Brookens SK; Boothby MR
    Immunometabolism; 2021; 3(2):. PubMed ID: 33717606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
    Gooptu M; Romee R; St Martin A; Arora M; Al Malki M; Antin JH; Bredeson CN; Brunstein CG; Chhabra S; Fuchs EJ; Ghosh N; Grunwald MR; Kanakry CG; Kekre N; McGuirk JP; McNiece IK; Mehta RS; Mielcarek M; Milano F; Modi D; Reshef R; Solomon SR; Schroeder MA; Waller EK; Inamoto Y; Soiffer RJ; Eapen M
    Blood; 2021 Jul; 138(3):273-282. PubMed ID: 34292325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of AMP-activated protein kinase in GVHD-causing T cells.
    Ramgopal A; Sun LK; Byersdorfer CA
    Immunometabolism (Cobham); 2022 Oct; 4(4):e00009. PubMed ID: 36275779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase Inhibition as Treatment for Acute and Chronic Graft-
    Braun LM; Zeiser R
    Front Immunol; 2021; 12():760199. PubMed ID: 34868001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD).
    Mhandire K; Saggu K; Buxbaum NP
    Metabolites; 2021 Oct; 11(11):. PubMed ID: 34822394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
    Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
    Front Immunol; 2021; 12():757836. PubMed ID: 34712243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells.
    Monlish DA; Beezhold KJ; Chiaranunt P; Paz K; Moore NJ; Dobbs AK; Brown RA; Ozolek JA; Blazar BR; Byersdorfer CA
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34291733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.